- Home
- ODV vs PHAT Comparison
ODV vs PHAT Comparison
Compare ODV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ODV | PHAT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ODV | PHAT |
|---|---|---|
| Price | $3.69 | $10.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.4M | 967.8K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $160.81 | $91.62 |
| Revenue Next Year | $60.22 | $59.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $1.34 | $2.21 |
| 52 Week High | $4.80 | $18.31 |
Technical Indicators
Market Signals| Indicator | ODV | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 35.03 |
| Support Level | $3.38 | $7.82 |
| Resistance Level | $4.04 | $12.77 |
| Average True Range (ATR) | 0.28 | 0.80 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 1.33 | 7.28 |
Price Performance
Historical ComparisonAbout ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.